Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Abroad (travel likely)RecruitingPHASE2
Conditions
Sickle Cell Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UAMS Medical Center, Little Rock, Arkansas, United States
The Foundation for Sickle Cell Disease, Hollywood, Florida, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Southern Specialty Research, Flowood, Mississippi, United States
Jacobi Medical Center, The Bronx, New York, United States
Study leads
Study Director
CSL Behring